Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A clinical guide to retatrutide's current regulatory status, FDA approval timeline, compounding legality under federal law, and what the drug label is expected to include.
Read clinical reviewHow the FDA and EMA are evaluating retatrutide differently, what Phase 3 TRIUMPH data must show, and when approval could realistically arrive for this triple-agonist obesity drug.
Read clinical reviewA detailed look at retatrutide's FDA regulatory path, from early clinical development through phase 3 trials, including safety data, labeling expectations, and projected approval timeline.
Read clinical reviewCurrent regulatory status of retatrutide (LY3437943) worldwide, including FDA review timeline, EMA interactions, phase 3 TRIUMPH trial program, and projected approval dates from Eli Lilly.
Read clinical reviewA comprehensive review of retatrutide's regulatory journey from 2020 through 2026, including FDA status, Phase 2 and Phase 3 trial milestones, and expected labeling details.
Read clinical reviewA clinical breakdown of retatrutide's regulatory path, patent protections, and legal hurdles facing Eli Lilly's triple-agonist GLP-1/GIP/glucagon receptor drug.
Read clinical reviewEverything clinicians and patients need to know about retatrutide's regulatory timeline, Phase 2 efficacy data, Phase 3 TRIUMPH program, expected FDA submission, and post-market safety requirements.
Read clinical review